FDA-Drug2026-04-15Class IIPROCESSING DEFECT
Cipla Lanreotide Injection 120 mg recalled for sterility assurance defect
What this means
Cipla USA is recalling specific lots of Lanreotide Injection (120 mg) because the manufacturer did not follow proper visual inspection procedures during production. This means the medication may not meet sterility standards and could potentially be contaminated.
- Check if you have Lanreotide Injection with one of the recalled lot numbers listed on the FDA website or your pharmacy receipt.
- Do not use recalled doses. Contact your doctor or pharmacist immediately for instructions on what to do.
- If you have already used this medication, call your doctor to discuss any health concerns.
The agency's original wording
Hazard
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
Intended for
Adults
Illnesses reported
None reported
Sold states
Nationwide in the USA
Manufactured in
10 Independence Blvd, Warren, NJ, United States
Products
Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-filled syringe, Single dose only, Rx Only, Manufactured by: Pharmathen International, S.A., Rodopi, Greece. Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC 69097-906-67
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0423-2026More Cipla recalls
- FDA-Drug2026-07-08Cipla Cinacalcet Hydrochloride 60 mg tablets recalled for N-nitroso impurity above safe limits
- FDA-Drug2026-07-08Cipla Cinacalcet Hydrochloride 90 mg tablets recalled for N-nitroso impurity above acceptable limits
- FDA-Drug2026-07-08Cipla Cinacalcet Hydrochloride 30 mg tablets recalled for N-nitroso impurity
Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.